tbuckley/cabot-search huggingface dataset:
Hematology
Authors: William Dameshek
Journal: New England Journal of Medicine (1947)

Hemorrhagic DiseasesAs previously stated the hemorrhagic diseases may be classified as those due to a defect, usually a reduction, in the blood platelets, to a defect in the coagulation factors of the blood and to a disturbance of the capillaries.91 Thrombocytopenic Disorders Qualitative abnormalities of the platelets undoubtedly exist, but they are exceedingly rare as compared with quantitative changes. Marked reductions in blood platelets (thrombocytopenia) occur in a number of conditions and may be due to bone-marrow disease, such as hypoplasia, aplasia, leukemia or other infiltration; deficiency of liver-extract principle (pernicious anemia), iron or certain components of the vitamin . . .
Resource and reimbursement barriers to comprehensive cancer care (CCC) delivery: An Association of Community Cancer Centers (ACCC) survey research analysis.
Authors: Al Bowen Benson, Leigh Boehmer, Latha Shivakumar, Julia Rachel Trosman, Christine B. Weldon, Elizabeth A. Hahn, Sheetal Mehta Kircher
Journal: Journal of Clinical Oncology (2020)

2075 Background: CCC delivery is recommended in guidelines, required by accreditation bodies, and essential for high-quality cancer management. Barriers, such as insufficient reimbursement and lack of specialist staff, prevent consistent access to and delivery of CCC, particularly supportive oncology services. Challenges especially persist in community programs, where access to philanthropy and similar funding is limited. ACCC conducted a representative survey of its member programs to elucidate capacity and barriers to CCC delivery in the community/academic setting in order to inform policy and value-based payment reform. Methods: Survey development methodology included item generation with expert review, iterative piloting and cognitive interviews to achieve content and internal validity. An online survey was piloted at the ACCC 2018 Annual Meeting and sent to member programs via email link. The final survey included 22 questions on availability and funding for supportive services. Twenty-seven supportive oncology services were assessed for availability, reasons not offered, reimbursement/funding and patient payment. Analyses were conducted with SAS. Results: 172 of 704 ACCC member programs responded and completed the majority of survey as of 10/7/19. Despite a high proportion of programs offering supportive oncology services, gaps between cost and reimbursement were present for all (Table). Deficits in reimbursement are compensated by patient out-of-pocket payments, grants and donations. Most centers report needing more staffing in psychology (61%), social work (60%), navigation (59%), nutrition (57%), palliative care (56%), genetic counseling (52%), and financial counseling (53%). Gaps were observed regardless of region or practice type. Conclusions: There is a lack of sufficient reimbursement, staffing, and budget to provide CCC across the U.S., regardless of region or practice type. Oncology care models and reimbursement policies must include CCC services to optimize delivery of care. [Table: see text]
ROBERT WHYTT OF EDINBURGH
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Women's health specialty, other issues on agenda of 'reframing' conference
Authors: A. A. Skolnick
Journal: JAMA (1992)

SEVERAL HUNDRED health care providers, medical school faculty, philosophers, and other scholars are expected to convene in Chicago, Ill, this week (October 15 through 17) to debate whether a medical specialty in women's health should be created. The conference, "Reframing Women's Health: Multidisciplinary Research and Practice," is sponsored by the University of Illinois at Chicago's Center for Research on Women and Gender. Its purpose is to explore strategies for enhancing research and clinical practice in women's health. Much of the first day of the meeting will be taken up by discussions on the need for a specialty in women's health and what kind of curricula would be necessary for establishing such a specialty. "This is the first national meeting that focuses on the creation of a women's health specialty," says Alice Dan, PhD, conference chair and director of the Center for Research on Women and Gender. On the second day,
Medical Courtesy.
Authors: None J. S. W.
Journal: JAMA (1898)

Boston, Jan. 10, 1898. <h3>To the Editor:</h3> —In theJournalof January 8, page 104, "Medical Courtesy," I would suggest adding to the answer, but the newcomer should first leave or send his card as an introduction or announcement of his coming. Respectfully, <h3>Ans.</h3> —Amendment is accepted.
Modified Factor VIII and Factor IX recombinant products
Authors: Elena Santagostino, Maria Elisa Mancuso
Journal: HemaSphere (2018)

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations
Authors: A. Spanos
Journal: JAMA (1989)

We analyzed data from the records of 422 patients with acute bacterial or viral meningitis. A cerebrospinal fluid (CSF) glucose level less than 1.9 mmol/L, a CSF-blood glucose ratio less than 0.23, a CSF protein level greater than 2.2 g/L, more than 2000 × 10<sup>6</sup>/L CSF leukocytes, or more than 1180 × 10<sup>6</sup>/L CSF polymorphonuclear leukocytes were individual predictors of bacterial infection with 99% certainty or better. Although any one of these tests could rule in bacterial meningitis with high probability, none could rule it out. To better predict whether a patient has bacterial vs viral infection, we developed a logistic multiple regression model using CSF-blood glucose ratio, total polymorphonuclear leukocyte count in CSF, age, and month of onset. This proved highly reliable when validated in an independent test sample, with an area under receiver operating characteristic curve of 0.97. The model should allow physicians to differentiate between acute viral and acute bacterial meningitis with greater accuracy. (<i>JAMA</i>. 1989;262:2700-2707)
CARPOMETACARPAL DISLOCATION
Authors: Edward H. McLean
Journal: JAMA (1922)

Cases of multiple dislocations at the carpometacarpal articulation are of sufficiently rare occurrence to warrant their being recorded for statistical reasons. A farmer, aged 40, was injured while pulling stumps. He was using a puller in which a 14 foot pole acted as a lever. The chain by which two heavy farm horses were hitched to the pole parted, releasing the pole, which struck the patient on the back of the right hand, right forearm, and right lower thorax. He was thrown violently to the ground, striking on the left hand with the arm outstretched. The injuries sustained consisted of fractures of several ribs on the right side, of the left clavicle, and of the right ulna laceration of muscles of the right forearm, laceration and contusion of the right hand, and the dislocation to be described, occurring in the right hand. On account of the marked swelling of the
Halothane Hepatitis
Authors: J. G. Reves
Journal: JAMA (1973)

<h3>To the Editor.—</h3> The failure by Walton et al (225:494, 1973) to demonstrate lymphocyte stimulation in subjects considered to have halothane hepatitis is predictable. Although the hepatic failure following halothane has been attributed to a hypersensitivity reaction by authorities,<sup>1,2</sup>arguments for an immunological basis of halothane hepatitis are not convincing based on such observations as an increased incidence of repeated exposure, eosinophilia, fever, granuloma formation, arthralgia, rashes, and circulating antimitochondrial antibodies. These are all nonspecific signs and have not been helpful in elucidating a mechanism of hepatic cell damage following halothane. Halothane hypersensitivity has not been well documented. In only two cases have positive provocation studies been reported,<sup>3,4</sup>and although temporal relationship of halothane administration to exacerbation of symptoms is suggestive, immunological studies demonstrating an immediate or delayed hypersensitivity reaction have not been documented.
Regional Notes
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-driven secondary adjuvant treatment with docetaxel in early breast cancer (BrCa).
Authors: Bjorn Naume, Marit Synnestvedt, Ragnhild Sorum Falk, Gro Wiedswang, Kjetil Weyde, Terje Risberg, Christian Kersten, Ingvil Mjaaland, Lise Vindi, Hilde H. Sommer, Anna Barbro Saetersdal, Cecilie Bendigtsen Schirmer, Jahn M. Nesland, Erik Andreas Wist, Elin Borgen
Journal: Journal of Clinical Oncology (2014)

11011 Background: Presence of DTCs in bone marrow (BM) predicts reduced survival in early BrCa. The present study explores the use of DTCs to identify adjuvant (adj) insufficiently treated patients (pts) to be offered secondary adj treatment (Tx), and as a surrogate marker for Tx response. Methods: In this prospective trial, 1,121 early BrCa pts were enrolled after completion of 6 cycles of adj FEC chemotherapy from Oct 2003-08. BM aspiration was performed 8-12 weeks after FEC (BM1), followed by a second BM aspiration 6 months (mo) later (BM2). Presence of DTCs in BM was determined by immunocytochemistry using pan-cytokeratin mAbs. If ≥1 DTCs were present at BM2, 6 cycles (mean 5.8; range 3-6) of docetaxel (D)(100 mg/m2, 3qw) was administered, followed by DTC analysis 1 mo and 13 mo after last D infusion (post-Tx). The primary endpoint was disease free survival (DFS). Log-rank statistics and Cox proportional-hazard model were used to compare outcome in pts treated with D with no DTCs after Tx to pts with DTC persistence, and in all pts according to primary tumor factors and DTC status. Results: Of 1,067 pts with available FU information (median 80.6 mo; end of FU Nov 2012) and a DTC result at BM2, 8.5% were DTC pos at BM1 and 7.2% at BM2. DTC pos pts at BM2 had higher pT- and pN-stage compared to BM2 neg pts (p=0.035 and p=0.098). Of 72 D-treated pts analyzed for DTCs after Tx, 15 (21%) had persistent DTCs. Pts with remaining DTCs had markedly reduced DFS (47% with relapse) compared to pts with no DTCs post-Tx (HR 6.9, 95% CI 2.2-21.7). Only 8.8% of D-treated pts with no DTCs post-Tx relapsed, compared to 12.7% of pts in the favorable group with no DTCs both at BM1 and BM2 (p=0.378, log rank). Separate analyses of pts with DTC neg status at BM2, showed that only ER neg pts with DTC pos status at BM1 had reduced survival, compared to those with no DTCs at BM1 (p=0.029). Conclusions: DTC status detects high-risk pts after FEC chemotherapy and DTC monitoring status after secondary Tx with D correlated strongly with survival. The results indicate that D contributes to improved prognosis for high-risk pts and emphasize the potential for DTC analysis as a surrogate marker for treatment effect in adj BrCa. Clinical trial information: NCT00248703.
P1.01-87 A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
Authors: F. Robert, M. Jerome, D. Miley, M. Harris, B. Simpson, B. Adams, C. Theuer, G. Sherwood
Journal: Journal of Thoracic Oncology (2018)
Colonoscopy
Authors: Douglas Rex
Journal: Endoscopy (2013)

A large number of high-quality studies important to colonoscopy were presented at Digestive Disease Week (DDW) 2013, and the topics addressed by these studies reflect current controversies in colonoscopic practice. Thus, bowel preparation, quality measurements (particularly factors affecting adenoma detection), polypectomy technique, serrated polyps, real-time histology, and water immersion were covered in great detail. Studies covered here reflect the author’s perception of those providing new data or describing new approaches to current controversies in colonoscopy.
Websites violate US laws banning treatment claims
Authors: F. Charatan
Journal: BMJ (2001)

Drug companies neglect research into diseases affecting the poor 154, 254, 272, 217, Drugs companies are failing to develop new drugs for diseases that predominantly affect poor people because they are not profitable enough, says a report from the international medical aid agency Médecins Sans Frontières."Drugs are not developed according to public health need, but according to profitability," said Dr Bernard Pécoul, director of the agency's Campaign for Access to Essential Medicines.The report describes the research and development activities of 11 major pharmaceutical companies, representing combined sales of nearly $117bn (£78bn).The medical aid agency specifically asked them for the overall resources devoted to malaria, tuberculosis, sleeping sickness, Chagas' disease, and leishmaniasis.Eight of the 11 companies spent nothing in the last financial year on research and development on sleeping sickness, leishmaniasis, or Chagas' disease.One company did not answer the question.Two reported spending on malaria.Five reported spending on tuberculosis, but seven reported spending less than 1% of their research and development budget on any of the five diseases highlighted.Meanwhile a survey by the Pharmaceutical Research and Manufacturers of America showed that in 2000 there were eight drugs in development for impotence and erectile dysfunction, seven for obesity, and four for sleep disorders.
Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection
Authors: K Ohnishi
Journal: Hepatology (1996)

To assess the efficacy of ultrasound-guided percutaneous acetic acid (15%, 20%, 30%, 40%, and 50% in concentration) injection for a large nodular hepatocellular carcinoma (HCC), percutaneous acetic acid injection was performed using 15% to 50% acetic acid in 28 patients who had one single nodular HCC larger than 3 cm or one main tumor with fewer than two HCCs smaller than 3 cm during the past 7.5 years; the main tumor was slightly hypervascular in nine patients and was highly hypervascular, showing viable cancer cells despite transcatheter arterial embolization in 19 patients. During the series of treatment sessions for each patient, the same concentration of acetic acid was used. Eight (89%) of nine slightly hypervascular main tumors, 18 (95%) of 19 highly hypervascular main tumors, and all 14 small tumors were treated successfully. No serious complications occurred as a direct sequela to acetic acid injection. The 1-, 2- and 3-year recurrence rate from the original main tumor was 0%, 20%, and 20%, respectively, in patients treated with percutaneous acetic acid injection alone and 12%, 24%, and 24% in patients treated with percutaneous acetic acid injection after transcatheter arterial embolization (P = NS). The 1-, 2-, 3-, 4-, and 5-year survival rates were 100%, 80%, 80%, 80%, and 0%, respectively, in the former and 90%, 81%, 81%, 61%, and 61% in the latter (P = NS). Percutaneous acetic acid injection (15% to 50%) may be an effective therapy for slightly hypervascular nodular HCCs larger than 3 cm and highly hypervascular nodular HCCs larger than 3 cm that remain partly viable after transcatheter arterial embolization.
Dear-Reply
Authors: Selma Harrison Calmes
Journal: JAMA (1983)

<h3>In Reply.—</h3> I am at a loss to explain the difference between Dr Janis' experience and mine. I have practiced medicine for 18 years in the South, East, and West in a variety of institutional settings and have never heard a male patient called<i>dear</i>. I certainly agree that our highly technological hospitals are causing patients to feel anonymous. What better way to maintain the patients' individualities than by using a title and their last name as Dr Clowney suggests? Language reflects our culture and society. Women's roles in our society have changed since the 1960s, but our language lags behind this change. One important example of this lag is the use of<i>dear</i>. Many women consider being called<i>dear</i>by a man from whom they are purchasing some service, be it health care or stocks and bonds, demeaning because it reflects the paternalistic view of women— women must be
Altruism, self-interest, and medical ethics
Authors: J. D. Tiemstra
Journal: JAMA (1988)

<h3>In Reply.</h3> —I am pleased that Dr Tiemstra found some points of agreement with my editorial. I am sorry he missed the major thrust of my argument. Dr Tiemstra draws the erroneous inference that I favor paternalism because I emphasize the dependence, vulnerability, and exploitability of the sick person. Rather, I hold that those features of illness impose the obligation to enhance the autonomy of the patient.<sup>1</sup> Dr Tiemstra denies that there is something special about being ill and being healed. He ignores the special nature of the invasion of personal privacy that a medical education entails. He equates access to a knowledge of pipes and drains, or to various business procedures, with access to knowledge of a person's body, emotional history, or state of suffering. The comment about student selection is gratuitous. However students are selected, once admitted they are morally bound to observe the obligations of being
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in <i>NPM1</i> Mutant Leukemia
Authors: Michael W.M. Kühn, Evelyn Song, Zhaohui Feng, Amit Sinha, Chun-Wei Chen, Aniruddha J. Deshpande, Monica Cusan, Noushin Farnoud, Annalisa Mupo, Carolyn Grove, Richard Koche, James E. Bradner, Elisa de Stanchina, George S. Vassiliou, Takayuki Hoshii, Scott A. Armstrong
Journal: Cancer Discovery (2016)

Abstract Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3 are frequently highly expressed and mutated in acute myeloid leukemia (AML). Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in the Nucleophosmin (NPM1) gene, and FLT3 is concomitantly mutated in approximately 60% of these cases. Little is known about how mutant NPM1 (NPM1mut) cells maintain aberrant gene expression. Here, we demonstrate that the histone modifiers MLL1 and DOT1L control HOX and FLT3 expression and differentiation in NPM1mut AML. Using a CRISPR/Cas9 genome editing domain screen, we show NPM1mut AML to be exceptionally dependent on the menin binding site in MLL1. Pharmacologic small-molecule inhibition of the menin–MLL1 protein interaction had profound antileukemic activity in human and murine models of NPM1mut AML. Combined pharmacologic inhibition of menin–MLL1 and DOT1L resulted in dramatic suppression of HOX and FLT3 expression, induction of differentiation, and superior activity against NPM1mut leukemia. Significance: MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1mut AML. Combinatorial small-molecule inhibition has synergistic on-target activity and constitutes a novel therapeutic concept for this common AML subtype. Cancer Discov; 6(10); 1166–81. ©2016 AACR. See related commentary by Hourigan and Aplan, p. 1087. This article is highlighted in the In This Issue feature, p. 1069
Indwelling peritoneal (Tenckhoff) dialysis catheter. Experience with 24 patients
Authors: T. E. Brewer
Journal: JAMA (1972)

The temporary Tenckhoff catheter has been utilized for intermittent peritoneal dialysis in 24 patients for periods from 1 to 14 months. Control of uremia has been comparable to our past experience with the repeated trocar puncture method. Although infection remains the most significant problem, it is avoidable by strict attention to sterile dialysis procedure and careful education of the patients concerning the daily care of their catheter and appreciation of its importance. The risk of infection under these circumstances is comparable to that of external arteriovenous shunts in hemodialysis. Our experience with the temporary Tenckhoff catheter warrants the conclusion that this catheter can be safely utilized and that peritoneal dialysis is an acceptable alternative or adjunct to hemodialysis.
AIDS and compassion
Authors: G. Friedland
Journal: JAMA (1988)

FROM the outset of the epidemic of the acquired immunodeficiency syndrome (AIDS), there has been continuing concern about a demonstrated personal, professional, and societal lack of compassion toward AIDS patients. Compassion, defined as a "deep feeling for and understanding of misery or suffering and the concomitant desire to promote its alleviation,"<sup>1</sup>is assumed in the care of the sick and is a basic tenet of our profession. Yet, lack of compassion toward AIDS patients and persons infected with human immunodeficiency virus (HIV) remains. Why is this so? Why is AIDS different from other illnesses? I believe there are three principal reasons. First, there is a continuing<i>fear of transmission</i>through routes that do not exist or are extremely infrequent sources of infection. This fear is prodded by reports in the media and is a consequence of insufficient educational efforts and confusion about the facts. It stems from a deep